NCT06662877 2024-10-29
Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment
Sun Yat-sen University
Phase 2/3 Not yet recruiting
Sun Yat-sen University
Fujian Cancer Hospital
Shanghai University of Traditional Chinese Medicine
Taizhou Hospital
ChineseAMS
Hebei Medical University
Peking University
Japan Clinical Cancer Research Organization
Eastern Network of Cancer Immunological Therapy, Japan